Instrument Inactif

Autres langues Silence Therapeutics plc London S.E.

Actions

GB0008433350

Recherche biotechnologique et médicale

Cours en clôture London S.E.
- ^GBX	-

11/09	Les actions européennes cotées aux États-Unis sous forme d'ADR progressent lors de la séance de vendredi	MT
09/09	Les actions européennes cotées aux États-Unis sous forme d'American Depositary Receipts reculent lors de la séance de mercredi	MT

Autres langues

11/09	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
09/09	European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
09/09	Gestern an der Wall Street: Geopolitik belastet den Wochenauftakt
09/09	Ayer en Wall Street: la geopolítica lastra el inicio de la semana
08/09	European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading
02/09	Silence Therapeutics to Participate in Three September Investor Conferences
31/08	European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading
25/08	European Equities Traded in the US as American Depositary Receipts Rise Slightly in Tuesday Trading
18/08	European Equities Traded in the US as American Depositary Receipts Head Lower in Tuesday Trading
17/08	Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional ADSs
14/08	Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
13/08	European Equities Traded in the US Rise in Thursday Trading
12/08	UK's Silence Therapeutics Prices $175 Million Offering in US
12/08	Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
11/08	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
11/08	Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says
10/08	Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
10/08	Silence Therapeutics' Divesiran to Treat Polychthemia Vera Meets Primary, Secondary Endpoints
10/08	Top Midday Gainers
10/08	European Equities Traded in the US as American Depositary Receipts Edge Higher in Monday Trading
10/08	Silence Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
10/08	Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
10/08	Silence Therapeutics Announces Positive Topline Results from Phase 2 Sanreco Trial of Divesiran in Polycythemia Vera
10/08	Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
09/08	Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera